Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection.
Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, Sangha N, Kim M, Froehler MT, Schwartz NE, Clark WM, Kircher CE, Yang M, Massaro L, Lu XY, Rippon GA, Broderick JP, Butcher K, Lansberg MG, Liebeskind DS, Nouh A, Schwamm LH, Campbell BCV; TIMELESS Investigators. Albers GW, et al. Among authors: purdon b. N Engl J Med. 2024 Feb 22;390(8):701-711. doi: 10.1056/NEJMoa2310392. Epub 2024 Feb 8. N Engl J Med. 2024. PMID: 38329148 Clinical Trial.
Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design.
Yeatts SD, Broderick JP, Chatterjee A, Jauch EC, Levine SR, Romano JG, Saver JL, Vagal A, Purdon B, Devenport J, Khatri P. Yeatts SD, et al. Among authors: purdon b. Int J Stroke. 2018 Aug;13(6):654-661. doi: 10.1177/1747493018765269. Epub 2018 Mar 23. Int J Stroke. 2018. PMID: 29570044
Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr, Starr M, Mejilla J, Broderick J, Chatterjee A, Jauch EC, Levine SR, Romano JG, Saver JL, Vagal A, Purdon B, Devenport J, Pavlov A, Yeatts SD; PRISMS Investigators. Khatri P, et al. Among authors: purdon b. JAMA. 2018 Jul 10;320(2):156-166. doi: 10.1001/jama.2018.8496. JAMA. 2018. PMID: 29998337 Free PMC article. Clinical Trial.
A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design.
Albers GW, Campbell BC, Lansberg MG, Broderick J, Butcher K, Froehler MT, Schwamm LH, Nouh AM, Liebeskind DS, Toy F, Yang M, Massaro L, Schoeffler M, Purdon B. Albers GW, et al. Among authors: purdon b. Int J Stroke. 2023 Feb;18(2):237-241. doi: 10.1177/17474930221088400. Epub 2022 Apr 1. Int J Stroke. 2023. PMID: 35262424
Tenecteplase for Stroke at 4.5 to 24 Hours. Reply.
Albers GW, Purdon B, Campbell BCV. Albers GW, et al. Among authors: purdon b. N Engl J Med. 2024 May 9;390(18):1729. doi: 10.1056/NEJMc2403602. N Engl J Med. 2024. PMID: 38718370 No abstract available.